The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots.

Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new ...

Shares of Novavax NVAX surged nearly 26% in pre-market trading today after its protein-based COVID-19 vaccine, Nuvaxovid, ...